Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA +5.22%48 Days Payable is 38.96 as of Mar. 2026, which is 78% below its 10-year median of 173.97. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, RUA Life Sciences ranks better than 55.35% on this metric.
The historical rank and industry rank for RUA Life Sciences's Days Payable or its related term are showing as below:
FRA:AOHA'
s Days Payable Range Over the Past 10 Years
Min: 76.81 Med: 173.97 Max: 305.53
Current: 76.81
During the past 13 years, RUA Life Sciences's highest Days Payable was 305.53. The lowest was 76.81. And the median was 173.97.
FRA:AOHA's Days Payable is ranked better than 55.35% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs FRA:AOHA: 76.81
RUA Life Sciences's Days Payable
declined
from Sep. 2024 (90.35) to Mar. 2026 (38.96).
It may suggest that RUA Life Sciencesaccelerated paying its suppliers.
RUA Life Sciences Days Payable Related Terms
RUA Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AOHA vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, RUA Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RUA Life Sciences's Days Payable for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) has a Days Payable of 38.96 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RUA Life Sciences and its competitors. This is 78% below median its historical median of 173.97. Over the past decade, RUA Life Sciences' Days Payable has ranged from 76.81 to 305.53. According to the industry distribution chart, RUA Life Sciences ranks #355 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 44.7%.
Is RUA Life Sciences' Days Payable too high?
RUA Life Sciences' current Days Payable of 38.96 is 78% below median its 10-year median of 173.97. Over the past 10 years, this metric has ranged from a low of 76.81 to a high of 305.53. The Medical Devices & Instruments industry median Days Payable is 67.87. RUA Life Sciences' value of 38.96 is 42.6% below this industry median. Based on the distribution chart, RUA Life Sciences ranks #355 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #355 out of 795 companies for Days Payable. This puts RUA Life Sciences in the upper half of its industry. The industry median Days Payable is 67.87. RUA Life Sciences' value of 38.96 is 42.6% below this benchmark. Historically, RUA Life Sciences' own Days Payable has ranged from 76.81 to 305.53 over the past decade. While the company's 10-year median is 173.97 vs. the industry median of 67.87, RUA Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RUA Life Sciences's current Days Payable of 38.96 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current Days Payable is 38.96, which is 78% below median its own 10-year median of 173.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.24 — trading 72.9% above its estimated fair value. The current Days Payable is 38.96, which is 78% below median its 10-year median of 173.97 and 42.6% below the Medical Devices & Instruments industry median of 67.87. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Days Payable is 38.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
Days Payable: 38.96 (78% below median its 10-year median of 173.97)
GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
Industry Position: 42.6% below the Medical Devices & Instruments median (#355 of 795)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score
Get the complete analysis for FRA:AOHA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
